Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Strimvelis regulatory update

June 6, 2016 7:00 AM UTC

The European Commission approved Strimvelis from GlaxoSmithKline to treat severe combined immunodeficiency (SCID) due to adenosine deaminase deficiency (ADA-SCID) for use in patients for whom a matched bone marrow donor is not available. The ultra-rare disease is caused by inheritance of 2 mutant copies of the gene encoding ADA and results in an inability to make lymphocytes. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article